Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Homayoun Zargar, Kamran Zargar-Shoshtari, Yair Lotan, Jay B. Shah, Bas W. van Rhijn, Siamak Daneshmand, Philippe E. Spiess, Peter Black, Adrian S. Fairey, Laura S. Mertens, Simon Horenblas, Colin P. Dinney, Maria C. Mir, Cesar E. Ercole, Andrew J. Stephenson, Laura Maria Krabbe, Michael S. Cookson, Niels Erik Jacobsen, Daniel A. Barocas, Joshua GriffinJeff M. Holzbeierlein, Jeffrey S. Montgomery, Todd M. Morgan, Nikhil Vasdev, Andrew C. Thorpe, Jonathan Aning, Evan Y. Yu, Jonathan L. Wright, Evanguelos Xylinas, Nicholas J. Campain, Farshad Pourmalek, John S. McGrath, Wassim Kassouf, Marc A. Dall'Era, Jo An Seah, Srikala S. Sridhar, Pranav Sharma, Shahrokh F. Shariat, Scott North, Petros Grivas, Nilay Gandhi, Trinity J. Bivalacqua

Research output: Contribution to journalArticle

Abstract

Purpose We assessed survival dependent on pathological response after neoadjuvant chemotherapy in a large multicenter patient cohort, with a particular focus on the difference between the absence of residual cancer (pT0) and the presence of only nonmuscle invasive residual cancer (pTa, pTis, pT1). Materials and Methods We retrospectively reviewed records of patients with urothelial cancer who received neoadjuvant chemotherapy and underwent radical cystectomy at 19 contributing institutions from 2000 to 2013. Patients with cT2-4aN0M0 and eventual pN0 disease were selected for this analysis. Estimated overall survival was compared between patients with pT0 and pTa/Tis/T1 disease. A multivariable Cox proportional hazards regression model for overall survival was generated to evaluate hazard ratios for variables of interest. Results Of 1,543 patients treated with neoadjuvant chemotherapy and radical cystectomy during the study period 257 had pT0N0 and 207 had pTa/Tis/T1N0 disease. The Kaplan-Meier mean estimates of overall survival for pT0 and pTa/Tis/T1 cases were 186.7 months (95% CI 145.9–227.6, median 241.1) and 138 months (95% CI 118.2–157.8, median 187.4), respectively (p=0.58). In the Cox proportional hazards regression model for overall survival pTa/Tis/T1N0 status (HR 0.36, 95% CI 0.23–0.67) and pT0N0 status (HR 0.28, 95% CI 0.17–0.47) compared to pT2N0 pathology, positive surgical margin (HR 1.75, 95% CI 1.07–2.86), and receiving a methotrexate, vinblastine, doxorubicin and cisplatin regimen compared to an “other” regimen (HR 0.45, 95% CI 0.27–0.76) were predictors of overall survival. Conclusions pTa/Tis/T1N0 and pT0N0 stage on the final cystectomy specimen are strong predictors of survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. We did not discern a statistically significant difference in overall survival when comparing these 2 end points.

Original languageEnglish (US)
Pages (from-to)886-893
Number of pages8
JournalJournal of Urology
Volume195
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • cystectomy
  • drug therapy
  • neoadjuvant therapy
  • urinary bladder neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?'. Together they form a unique fingerprint.

  • Cite this

    Zargar, H., Zargar-Shoshtari, K., Lotan, Y., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Spiess, P. E., Black, P., Fairey, A. S., Mertens, L. S., Horenblas, S., Dinney, C. P., Mir, M. C., Ercole, C. E., Stephenson, A. J., Krabbe, L. M., Cookson, M. S., Jacobsen, N. E., Barocas, D. A., ... Bivalacqua, T. J. (2016). Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1? Journal of Urology, 195(4), 886-893. https://doi.org/10.1016/j.juro.2015.10.133